AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36990493 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital percutaneous coronary intervention (PCI)
Number of subjects: 23887
Study 36990493 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy and statins at discharge
Number of subjects: 23887
Study 36990493 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, prior stroke, heart rate, Killip class, left ventricular ejection fraction (LVEF), recurrent myocardial ischaemia, recurrent myocardial infarction, heart failure (HF) during hospitalisation
Number of subjects: 23887
Study 36990493 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, prior renal dysfunction, history of HF, AMI classification, heart rate, Killip class, haemoglobin, LVEF, in-hospital PCI, HF during hospitalisation, HF worsening within 30 days after discharge, antiplatelet therapy, β blocker and statin use within 30 days after discharge
Number of subjects: 23887
Study 36990546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic somatic mosaicism (HSM) carriers
Number of subjects: 104
Study 36990546 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM assessment
Number of subjects: 104
Study 36990546 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM carriers
Number of subjects: 104
Study 36990554 — intervention group
Group type: COMPARATOR
Intervention: Standard planning
Number of subjects: 200
Study 36990554 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + simulation-based planning
Number of subjects: 200
Study 36990558 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitor valve
Number of subjects: 260
Study 36990576 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab after chemoradiotherapy
Number of subjects: 0
Study 36990576 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36990607 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36990609 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with definitive chemoradiotherapy (50·4 Gy in 28 fractions, five cycles of weekly intravenous paclitaxel [50 mg/m²])
Number of subjects: 42
Study 36990609 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with definitive chemoradiotherapy
Number of subjects: 42
Study 36990608 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1125
Study 36990608 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal antiandrogen (control)
Number of subjects: 1125
Study 36990610 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surveillance (initial endoscopy and subsequent endoscopies every 6 to 12 months)
Number of subjects: 270
Study 36990610 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic total gastrectomy
Number of subjects: 270
Study 36990610 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients
Number of subjects: 270
Study 36990622 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprenetapopt (4·5 g/day on days 1-4) and venetoclax (400 mg/day on days 1-28) with azacitidine (75 mg/m2)
Number of subjects: 49
Study 36990622 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprenetapopt and venetoclax with azacitidine
Number of subjects: 49
Study 36990930 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscadine grape extract supplement (MGES) - four tablets twice daily for 12 weeks
Number of subjects: 64
Study 36990930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 36990930 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscadine grape extract supplement (MGES)
Number of subjects: 64
Study 36991169 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS-05 (0.05-3.2 mg/kg)
Number of subjects: 48
Study 36991169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36991301 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy (PC)
Number of subjects: 195
Study 36991301 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 195
Study 36991301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy after PC
Number of subjects: 195
Study 36991380 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training (EXE) three times per week throughout pregnancy
Number of subjects: 219
Study 36991380 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counselling on physical activity (MOT) seven times during pregnancy
Number of subjects: 219
Study 36991380 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CON)
Number of subjects: 219
Study 36991390 — intervention group
Group type: EXPERIMENTAL
Intervention: NEO-201 (1 mg/kg, 1.5 mg/kg, 2 mg/kg) administered intravenously every two weeks in a 28-day cycle until DLT, disease progression, or patient withdrawal.
Number of subjects: 17
Study 36991390 — intervention group
Group type: EXPERIMENTAL
Intervention: NEO-201 treatment
Number of subjects: 17
Study 36991396 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of raisins daily for 6 months
Number of subjects: 0
Study 36991396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 0
Study 36991415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucous fistula refeeding (MFR) in high-output group
Number of subjects: 20
Study 36991415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucous fistula refeeding (MFR) in normal-output group
Number of subjects: 20
Study 36991415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 36991415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucous fistula refeeding (MFR)
Number of subjects: 20
Study 36991434 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention enabling care aides to lead quality improvement efforts over one year.
Number of subjects: 64
Study 36991434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 64
Study 36991450 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral dextromethorphan hydrobromide preoperatively, 30 mg at 8 h and 16 h postoperatively
Number of subjects: 160
Study 36991450 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 160
Study 36991453 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 280
Study 36991453 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing plus Substance-Free Activities Session plus Mindfulness (BSM)
Number of subjects: 280
Study 36991453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (for non-adherent individuals)
Number of subjects: 280
Study 36991460 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma surveillance photography (MSP) in addition to routine clinical surveillance
Number of subjects: 580
Study 36991460 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical surveillance without MSP
Number of subjects: 580
Study 36991490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready2Change-Methamphetamine (R2C-M) intervention, n = 98 ± 4; four to six telephone-delivered intervention sessions, R2C-M workbooks and MA information booklet
Number of subjects: 196
Study 36991490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready2Change-Methamphetamine (R2C-M) intervention
Number of subjects: 196
Study 36991490 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 98 ± 4; four to six ≤5-min telephone check-ins and MA information booklet including information on accessing further support
Number of subjects: 196
Study 36991490 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 36991547 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg subcutaneously once weekly after two step-up doses (0.06 and 0.3 mg/kg)
Number of subjects: 165
Study 36991547 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab with tocilizumab for first CRS event
Number of subjects: 165
Study 36991547 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab without tocilizumab for first CRS event
Number of subjects: 165
Study 36991547 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 165
Study 36992530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 13523
Study 36992530 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 13523
Study 36992541 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 166
Study 36992541 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ with ID
Number of subjects: 166
Study 36992541 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+
Number of subjects: 166
Study 36992541 — intervention group
Group type: COMPARATOR
Intervention: HIV- and ID
Number of subjects: 166
Study 36992590 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized cognitive stimulation program (7 training sessions, 45 minutes each, over 15 days)
Number of subjects: 12
Study 36992749 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training (SMART) program conducted over 8 sessions via web-based video conference software
Number of subjects: 0
Study 36992749 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training (SMART) program
Number of subjects: 0
Study 36992761 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 102
Study 36992863 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of anastrozole (1 mg orally once a day)
Number of subjects: 1912
Study 36992863 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 years of anastrozole (1 mg orally once a day)
Number of subjects: 1912
Study 36992865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining same prescriptions
Number of subjects: 731
Study 36992865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill dispenser
Number of subjects: 731
Study 36992865 — intervention group
Group type: EXPERIMENTAL
Intervention: Finish previous refills first
Number of subjects: 731
Study 36992865 — intervention group
Group type: COMPARATOR
Intervention: Control group (not combining same prescriptions)
Number of subjects: 731
Study 36992865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-fill adherence
Number of subjects: 731
Study 36992865 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 731
Study 36992911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 0
Study 36992911 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Number of subjects: 0
Study 36993265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Number of subjects: 0
Study 36993265 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers
Number of subjects: 0
Study 36993265 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Feedback at Family Meals
Number of subjects: 0
Study 36993363 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 µg, sc)
Number of subjects: 62
Study 36993363 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.2 mL, sc)
Number of subjects: 62
Study 36993496 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 1300
Study 36993496 — intervention group
Group type: COMPARATOR
Intervention: Oxygen mask
Number of subjects: 1300
Study 36993617 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative ketamine infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544
Study 36993617 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544
Study 36993617 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative ketamine infusion
Number of subjects: 1544
Study 36993617 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 1544
Study 36993880 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal Mental Health for Refugee Women (PMH-RW) Project
Number of subjects: 0
Study 36993880 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures on depression (EPDS)
Number of subjects: 0
Study 36993880 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures on anxiety (GAD-7)
Number of subjects: 0
Study 36993880 — intervention group
Group type: EXPERIMENTAL
Intervention: City Birth Questionnaire
Number of subjects: 0
Study 36993880 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of events scale-revised (PTSD-R)
Number of subjects: 0
Study 36993880 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Item Personality Inventory-TIPI
Number of subjects: 0
Study 36993880 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic questionnaire
Number of subjects: 0
Study 36993886 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week mind-body based online intervention program consisting of 36 mind-body based micropractices
Number of subjects: 643
Study 36993886 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week mind-body based online intervention program
Number of subjects: 643
Study 36994205 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated whole-body
Number of subjects: 55
Study 36994730 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 infusion
Number of subjects: 50
Study 36994730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 36994923 — intervention group
Group type: COMPARATOR
Intervention: Preventive zinc supplementation (zinc sulfate, 10-15 mg daily)
Number of subjects: 219584
Study 36994923 — intervention group
Group type: COMPARATOR
Intervention: Preventive zinc supplementation
Number of subjects: 219584
Study 36994947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks (Q2W)
Number of subjects: 0
Study 36994947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 4 weeks (Q4W)
Number of subjects: 0
Study 36994947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lebrikizumab withdrawal)
Number of subjects: 0
Study 36995416 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle training (PFMT)
Number of subjects: 84
Study 36995416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions after initial assessment)
Number of subjects: 84
Study 36995469 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab (IL-23p19 subunit inhibitor)
Number of subjects: 0
Study 36995469 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab (IL-12/23p40 inhibitor)
Number of subjects: 0
Study 36995469 — intervention group
Group type: COMPARATOR
Intervention: risankizumab (IL-23p19 inhibitor)
Number of subjects: 0
Study 36995469 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 0
Study 36995567 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS) during food-related reappraisal task
Number of subjects: 32
Study 36995690 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CT-RT) in trial 9514
Number of subjects: 143
Study 36995690 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative image-guided radiotherapy (RT) in trial 0630
Number of subjects: 143
Study 36995690 — intervention group
Group type: COMPARATOR
Intervention: Pathologic complete response (pCR)
Number of subjects: 143
Study 36995739 — intervention group
Group type: EXPERIMENTAL
Intervention: Health4Her (alcohol brief intervention + lifestyle information)
Number of subjects: 558
Study 36995739 — intervention group
Group type: COMPARATOR
Intervention: Control (lifestyle information)
Number of subjects: 558
Study 36995742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiling and Aggregation (T&A) algorithms applied to rPPG signals
Number of subjects: 1315
Study 36995742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no T&A applied)
Number of subjects: 1315
Study 36995742 — intervention group
Group type: EXPERIMENTAL
Intervention: T&A algorithms for darker skin tones
Number of subjects: 1315
Study 36995743 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tool (COPD Web)
Number of subjects: 10
Study 36995872 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.04, 0.08, 0.16 mg/kg/week) for 1 year, followed by 0.16 mg/kg/week for 3 years
Number of subjects: 50
Study 36995872 — intervention group
Group type: COMPARATOR
Intervention: Somapacitan (0.16 mg/kg/week) after switching from daily GH
Number of subjects: 50
Study 36995872 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (0.034 mg/kg/day) for 3 years, then somapacitan (0.16 mg/kg/week) for 1 year
Number of subjects: 50
Study 36995971 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic limb movements in sleep
Number of subjects: 0
Study 36996150 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebilustat 100 mg/d for 28 days
Number of subjects: 60
Study 36996150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36996150 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebilustat
Number of subjects: 60
Study 36996185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel with AP 10-701
Number of subjects: 60
Study 36996185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel without AP 10-701
Number of subjects: 60
Study 36996185 — intervention group
Group type: COMPARATOR
Intervention: Euvax B hepatitis B vaccine (Control)
Number of subjects: 60
Study 36996236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic adjustment
Number of subjects: 157
Study 36996236 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based involvement
Number of subjects: 157
Study 36996239 — intervention group
Group type: EXPERIMENTAL
Intervention: LMCAD non-culprit group
Number of subjects: 429
Study 36996239 — intervention group
Group type: COMPARATOR
Intervention: No LMCAD group
Number of subjects: 429
Study 36996264 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 22055
Study 36996322 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily and selpercatinib 80 mg twice daily
Number of subjects: 14
Study 36996325 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPI) treatment for 4 weeks
Number of subjects: 81
Study 36996325 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent ctDNA at 4 weeks
Number of subjects: 81
Study 36996325 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from detected to undetected ctDNA by 4 weeks
Number of subjects: 81
Study 36996325 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA change
Number of subjects: 81
Study 36996373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months
Number of subjects: 80
Study 36996380 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 1311
Study 36996380 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus Abiraterone Acetate and Prednisone (AAP)
Number of subjects: 1311
Study 36996413 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Mobilization
Number of subjects: 0
Study 36996413 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 36996503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxymetazoline 0.1%
Number of subjects: 114
Study 36996503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 36996634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 39
Study 36996634 — intervention group
Group type: COMPARATOR
Intervention: Untreated MS controls
Number of subjects: 39
Study 36996664 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 61
Study 36996664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 36996864 — intervention group
Group type: EXPERIMENTAL
Intervention: RR-CHOP (Rituximab intensification on day 0 of the 1st cycle with R-CHOP-21)
Number of subjects: 92
Study 36996864 — intervention group
Group type: EXPERIMENTAL
Intervention: RR-CHOP
Number of subjects: 92
Study 36996935 — intervention group
Group type: EXPERIMENTAL
Intervention: Texas Sprouts intervention
Number of subjects: 2414
Study 36996935 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2414
Study 36997069 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab (interleukin-17 pathway inhibitor)
Number of subjects: 0
Study 36997247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatica preoperative MR scan (MR-based volumetry, Couinaud segmentation, liver tissue characteristics and operative planning tool)
Number of subjects: 0
Study 36997247 — intervention group
Group type: EXPERIMENTAL
Intervention: LiMAx test (hepatic functional capacity)
Number of subjects: 0
Study 36997247 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 36997252 — intervention group
Group type: EXPERIMENTAL
Intervention: mecobalamin (vitamin B)
Number of subjects: 0
Study 36997252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36997255 — intervention group
Group type: EXPERIMENTAL
Intervention: Online community-based exercise intervention (CBE) involving thrice weekly exercise (aerobic, resistance, balance, flexibility), biweekly personal training sessions, YMCA membership, wireless physical activity monitor, monthly educational sessions.
Number of subjects: 30
Study 36997255 — intervention group
Group type: EXPERIMENTAL
Intervention: Online community-based exercise intervention (CBE)
Number of subjects: 30
Study 36997260 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 625
Study 36997260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 36997386 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 85
Study 36997448 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss Collagen
Number of subjects: 40
Study 36997448 — intervention group
Group type: COMPARATOR
Intervention: No grafting material
Number of subjects: 40
Study 36997569 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-121 (oral probiotic formulation) administered once daily for 28 days
Number of subjects: 15